Entasis Drug Patent Portfolio
Entasis owns 1 orange book drug protected by 4 US patents Given below is the list of Entasis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US9309245 | Beta-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
| US9623014 | β-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
Latest Legal Activities on Entasis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Entasis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US9309245 |
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US10376499 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US9309245 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10376499 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US9309245 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US10376499 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US10376499 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US10376499 |
| Patent Term Extension Application under 35 USC 156 Filed | 24 Jul, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Feb, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2021 | US9968593 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2020 | US9623014 |
Entasis's Family Patents
Entasis Drug List
Given below is the complete list of Entasis's drugs and the patents protecting them.
1. Xacduro (copackaged)
Xacduro (copackaged) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(9 years from now)
| Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(9 years from now)
| Active |
| US9309245 | Beta-lactamase inhibitor compounds |
02 Apr, 2033
(7 years from now)
| Active |
| US9623014 | β-lactamase inhibitor compounds |
02 Apr, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xacduro (copackaged)'s drug page